ArticleESMO open2018
Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie.
Clémence Basse et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
29 papers cite it
this paperpooled ittrialcites it